Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum

Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum is organized by PVI, PeerView Institute for Medical Education.

Activity Release Date: June 4, 2023
Activity Expiration Date: July 3, 2024.

Activity Description:
While recurrent or advanced endometrial cancer (EC) has traditionally been associated with a poor prognosis, the use of immune checkpoint inhibition (ICI) in both monotherapy and combination approaches has led to improved outcomes. These gains have been well established in the second-line setting with multiple regulatory approvals, and ICIs have recently been shown to have an impact in the frontline setting, further altering the standard of care.

In this activity, based on a recent live symposium, a panel of experts provides participants with foundational knowledge on the mechanistic rationale and up-to-date evidence supporting the use of ICIs in patients with advanced EC. Through discussion of real-life patient cases, the faculty provides practical guidance on incorporating approved and emerging approaches into clinical practice. Featured topics include biomarker testing, clinical trial enrollment, patient/provider education, and management of immune-related adverse events.

Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Cite the rationales, therapeutic roles, and key efficacy/safety evidence supporting the use of immuno-oncology treatments and emerging approaches for patients with recurrent or advanced endometrial cancer
• Select personalized treatment options for patients with recurrent or advanced endometrial cancer, taking into consideration the latest evidence, guideline recommendations, and biomarker testing results
• Implement proactive, collaborative strategies to mitigate and manage immune-related adverse events associated with immunotherapy-based treatment.